ZA200205236B - Method for obtaining antigenic structures enhancing specific cross reactivity. - Google Patents
Method for obtaining antigenic structures enhancing specific cross reactivity. Download PDFInfo
- Publication number
- ZA200205236B ZA200205236B ZA200205236A ZA200205236A ZA200205236B ZA 200205236 B ZA200205236 B ZA 200205236B ZA 200205236 A ZA200205236 A ZA 200205236A ZA 200205236 A ZA200205236 A ZA 200205236A ZA 200205236 B ZA200205236 B ZA 200205236B
- Authority
- ZA
- South Africa
- Prior art keywords
- antigenic structure
- dendrimeric
- epitopes
- structure according
- belong
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 58
- 230000000890 antigenic effect Effects 0.000 title claims description 52
- 230000009260 cross reactivity Effects 0.000 title claims description 34
- 230000002708 enhancing effect Effects 0.000 title description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 179
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 85
- 239000000203 mixture Substances 0.000 claims description 51
- 239000000427 antigen Substances 0.000 claims description 36
- 102000036639 antigens Human genes 0.000 claims description 33
- 108091007433 antigens Proteins 0.000 claims description 33
- 102000014914 Carrier Proteins Human genes 0.000 claims description 31
- 108010078791 Carrier Proteins Proteins 0.000 claims description 31
- 238000009472 formulation Methods 0.000 claims description 22
- 230000021615 conjugation Effects 0.000 claims description 21
- 235000018102 proteins Nutrition 0.000 claims description 17
- 102000004169 proteins and genes Human genes 0.000 claims description 17
- 108090000623 proteins and genes Proteins 0.000 claims description 17
- 238000003786 synthesis reaction Methods 0.000 claims description 17
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 16
- 230000015572 biosynthetic process Effects 0.000 claims description 16
- 229960005486 vaccine Drugs 0.000 claims description 14
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 claims description 11
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 11
- 229940014800 succinic anhydride Drugs 0.000 claims description 11
- 125000006850 spacer group Chemical group 0.000 claims description 10
- 241000588650 Neisseria meningitidis Species 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 101710132601 Capsid protein Proteins 0.000 claims description 8
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 8
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 8
- 244000005700 microbiome Species 0.000 claims description 7
- 244000052769 pathogen Species 0.000 claims description 7
- 208000002672 hepatitis B Diseases 0.000 claims description 6
- 208000035473 Communicable disease Diseases 0.000 claims description 5
- 229920002307 Dextran Polymers 0.000 claims description 5
- 241000700721 Hepatitis B virus Species 0.000 claims description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 5
- 230000008878 coupling Effects 0.000 claims description 5
- 238000010168 coupling process Methods 0.000 claims description 5
- 238000005859 coupling reaction Methods 0.000 claims description 5
- 239000003488 releasing hormone Substances 0.000 claims description 5
- 241000700605 Viruses Species 0.000 claims description 4
- 230000001717 pathogenic effect Effects 0.000 claims description 4
- 241000725619 Dengue virus Species 0.000 claims description 3
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 3
- 208000005176 Hepatitis C Diseases 0.000 claims description 3
- 241000282414 Homo sapiens Species 0.000 claims description 3
- 239000004472 Lysine Substances 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 230000009885 systemic effect Effects 0.000 claims description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- 229940037003 alum Drugs 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229940021747 therapeutic vaccine Drugs 0.000 claims description 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 230000005784 autoimmunity Effects 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 241000711549 Hepacivirus C Species 0.000 claims 2
- 150000004676 glycans Chemical class 0.000 claims 2
- 229920001282 polysaccharide Polymers 0.000 claims 2
- 239000005017 polysaccharide Substances 0.000 claims 2
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 230000005847 immunogenicity Effects 0.000 description 34
- 230000004044 response Effects 0.000 description 30
- 241000699670 Mus sp. Species 0.000 description 23
- 230000005875 antibody response Effects 0.000 description 21
- 230000003053 immunization Effects 0.000 description 21
- 238000009448 modified atmosphere packaging Methods 0.000 description 20
- 238000002649 immunization Methods 0.000 description 19
- 235000019837 monoammonium phosphate Nutrition 0.000 description 19
- 238000002965 ELISA Methods 0.000 description 16
- 101001057305 Homo sapiens Microtubule-associated protein 1S Proteins 0.000 description 15
- 102100027228 Microtubule-associated protein 1S Human genes 0.000 description 15
- 230000037029 cross reaction Effects 0.000 description 15
- 108010067902 Peptide Library Proteins 0.000 description 13
- 210000000987 immune system Anatomy 0.000 description 12
- 238000006386 neutralization reaction Methods 0.000 description 12
- 230000009257 reactivity Effects 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 9
- 239000000412 dendrimer Substances 0.000 description 9
- 229920000736 dendritic polymer Polymers 0.000 description 9
- 230000002163 immunogen Effects 0.000 description 9
- HONKEGXLWUDTCF-YFKPBYRVSA-N (2s)-2-amino-2-methyl-4-phosphonobutanoic acid Chemical compound OC(=O)[C@](N)(C)CCP(O)(O)=O HONKEGXLWUDTCF-YFKPBYRVSA-N 0.000 description 8
- 101000616438 Homo sapiens Microtubule-associated protein 4 Proteins 0.000 description 8
- 102100021794 Microtubule-associated protein 4 Human genes 0.000 description 8
- 239000007822 coupling agent Substances 0.000 description 8
- 230000028993 immune response Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000002788 anti-peptide Effects 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 238000007619 statistical method Methods 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 108010055044 Tetanus Toxin Proteins 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 150000001718 carbodiimides Chemical class 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000001641 gel filtration chromatography Methods 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229940118376 tetanus toxin Drugs 0.000 description 3
- LLXVXPPXELIDGQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)benzoate Chemical compound C=1C=CC(N2C(C=CC2=O)=O)=CC=1C(=O)ON1C(=O)CCC1=O LLXVXPPXELIDGQ-UHFFFAOYSA-N 0.000 description 2
- LGGRPYXPOUIMKG-OJICBBQQSA-N (2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S,3R)-2-[[2-[[(2S,3S)-2-[[(2S,3S)-2-[[(2S)-4-amino-2-[[(2S)-6-amino-2-[[(2S,3R)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-1-[2-[[(2S,3S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-1-[(2S)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-4-oxobutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-oxobutanoyl]amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-methylpentanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]amino]-4-oxobutanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-N-[(2S)-1-[[(2S)-1-amino-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]pentanediamide Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N2CCC[C@H]2C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC4=CC=C(C=C4)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC5=CNC=N5)C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC6=CC=C(C=C6)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@@H]7CCCN7C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]([C@@H](C)O)N LGGRPYXPOUIMKG-OJICBBQQSA-N 0.000 description 2
- 241000710829 Dengue virus group Species 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 101710192597 Protein map Proteins 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 229940022399 cancer vaccine Drugs 0.000 description 2
- 238000009566 cancer vaccine Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- 101100057875 Caenorhabditis elegans asg-2 gene Proteins 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 241000710815 Dengue virus 2 Species 0.000 description 1
- 241000711557 Hepacivirus Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 101710085938 Matrix protein Proteins 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- FBVSXKMMQOZUNU-NSHDSACASA-N N2,N6-Bis{[(2-methyl-2-propanyl)oxy]carbonyl}lysine Chemical compound CC(C)(C)OC(=O)NCCCC[C@@H](C(O)=O)NC(=O)OC(C)(C)C FBVSXKMMQOZUNU-NSHDSACASA-N 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- -1 amino acid Boc- Chemical class 0.000 description 1
- 230000009833 antibody interaction Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229940031416 bivalent vaccine Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N ethyl formate Chemical compound CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002766 immunoenhancing effect Effects 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- LQRJAEQXMSMEDP-XCHBZYMASA-N peptide a Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)NCCCC[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C/C=1C=CC=CC=1)C(N)=O)C(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C\C1=CC=CC=C1 LQRJAEQXMSMEDP-XCHBZYMASA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
- C08G83/002—Dendritic macromolecules
- C08G83/003—Dendrimers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
- A61K2039/645—Dendrimers; Multiple antigen peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2000024220000242A CU23011A1 (es) | 2000-11-03 | 2000-11-03 | Método de obtención de estructuras antigénicas quemétodo de obtención de estructuras antigénicas que potencian la reactividad cruzada específica y su potencian la reactividad cruzada específica y su uso en formulaciones uso en formulaciones |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200205236B true ZA200205236B (en) | 2003-09-29 |
Family
ID=5459562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200205236A ZA200205236B (en) | 2000-11-03 | 2002-06-28 | Method for obtaining antigenic structures enhancing specific cross reactivity. |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1334727A2 (ja) |
| JP (1) | JP4099059B2 (ja) |
| KR (1) | KR100887591B1 (ja) |
| CN (1) | CN100387616C (ja) |
| AR (1) | AR031182A1 (ja) |
| AU (2) | AU1493802A (ja) |
| BR (1) | BR0107424A (ja) |
| CA (1) | CA2427539A1 (ja) |
| CU (1) | CU23011A1 (ja) |
| EA (1) | EA005313B1 (ja) |
| HK (1) | HK1058154A1 (ja) |
| MX (1) | MXPA03003849A (ja) |
| MY (1) | MY137709A (ja) |
| WO (1) | WO2002036160A2 (ja) |
| ZA (1) | ZA200205236B (ja) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU23297A1 (es) * | 2004-11-16 | 2008-07-24 | Ct De Inmunologa A Molecular | Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer |
| DE102007002726A1 (de) * | 2007-01-18 | 2008-07-31 | Bayer Schering Pharma Aktiengesellschaft | Neue Kaskaden-Polymer-Komplexe, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel |
| KR100836745B1 (ko) * | 2007-01-31 | 2008-06-10 | (주)두비엘 | Ｈｂｖ 백신 및 그의 제조 방법 |
| WO2008151389A1 (en) * | 2007-06-15 | 2008-12-18 | Macfarlane Burnet Institute For Medical Research And Public Health Limited | Chemically modified macromolecules |
| PL230663B1 (pl) | 2015-01-15 | 2018-11-30 | Univ Gdanski | Szczepionka, sposob jej otrzymywania, wyizolowane chimeryczne bialko, wektor ekspresyjny, zestaw zawierajacy szczepionke oraz kompozycja do zastosowania w profilaktyce zakazen powodowanych przez HCV i/lub HBV |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3786000T3 (de) * | 1986-08-18 | 1997-08-21 | Dow Chemical Co | Conjugate dichter Sterne. |
| CU22629A1 (es) * | 1997-03-06 | 2000-12-22 | Ct Ingenieria Genetica Biotech | Formulaciones inmunopotenciadoras para uso vacunal |
-
2000
- 2000-11-03 CU CU2000024220000242A patent/CU23011A1/es unknown
-
2001
- 2001-10-30 MY MYPI20015012A patent/MY137709A/en unknown
- 2001-11-01 CA CA002427539A patent/CA2427539A1/en not_active Abandoned
- 2001-11-01 EA EA200300535A patent/EA005313B1/ru not_active IP Right Cessation
- 2001-11-01 EP EP01983427A patent/EP1334727A2/en not_active Withdrawn
- 2001-11-01 MX MXPA03003849A patent/MXPA03003849A/es not_active Application Discontinuation
- 2001-11-01 AU AU1493802A patent/AU1493802A/xx active Pending
- 2001-11-01 BR BR0107424-5A patent/BR0107424A/pt not_active IP Right Cessation
- 2001-11-01 AR ARP010105120A patent/AR031182A1/es unknown
- 2001-11-01 WO PCT/CU2001/000007 patent/WO2002036160A2/es active Application Filing
- 2001-11-01 KR KR1020027008651A patent/KR100887591B1/ko not_active IP Right Cessation
- 2001-11-01 AU AU2002214938A patent/AU2002214938B2/en not_active Ceased
- 2001-11-01 CN CNB018039782A patent/CN100387616C/zh not_active Expired - Fee Related
- 2001-11-01 JP JP2002538969A patent/JP4099059B2/ja not_active Expired - Fee Related
-
2002
- 2002-06-28 ZA ZA200205236A patent/ZA200205236B/en unknown
-
2004
- 2004-02-13 HK HK04101011.9A patent/HK1058154A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| MY137709A (en) | 2009-02-27 |
| MXPA03003849A (es) | 2004-10-15 |
| EA200300535A1 (ru) | 2003-10-30 |
| JP4099059B2 (ja) | 2008-06-11 |
| BR0107424A (pt) | 2002-10-15 |
| EP1334727A2 (en) | 2003-08-13 |
| AU2002214938B2 (en) | 2006-04-13 |
| KR100887591B1 (ko) | 2009-03-10 |
| CN1446094A (zh) | 2003-10-01 |
| EA005313B1 (ru) | 2004-12-30 |
| WO2002036160A2 (es) | 2002-05-10 |
| AR031182A1 (es) | 2003-09-10 |
| HK1058154A1 (en) | 2004-05-07 |
| CN100387616C (zh) | 2008-05-14 |
| CA2427539A1 (en) | 2003-05-01 |
| AU1493802A (en) | 2002-05-15 |
| KR20020080360A (ko) | 2002-10-23 |
| WO2002036160A3 (es) | 2003-05-30 |
| JP2004513897A (ja) | 2004-05-13 |
| CU23011A1 (es) | 2004-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100290632B1 (ko) | 면역성이약한항원공액체와이를포함하는합성펩티드담체와백신 | |
| Lowell et al. | Peptides bound to proteosomes via hydrophobic feet become highly immunogenic without adjuvants. | |
| TW200533681A (en) | Immunogenic peptide carrier conjugates and methods of producing same | |
| Chong et al. | A strategy for rational design of fully synthetic glycopeptide conjugate vaccines | |
| JP2003529319A (ja) | ＨＩＶ−１ｇｐ４１を標的化する広範に中和する抗体を誘発する方法 | |
| CA2186595A1 (en) | Synthetic peptide based immunogens for the treatment of allergy | |
| Partidos et al. | The effect of orientation of epitopes on the immunogenicity of chimeric synthetic peptides representing measles virus protein sequences | |
| JPH05505188A (ja) | 合成ポリペプチド | |
| Haro et al. | Liposome entrapment and immunogenic studies of a synthetic lipophilic multiple antigenic peptide bearing VP1 and VP3 domains of the hepatitis A virus: a robust method for vaccine design | |
| Hudecz | Manipulation of epitope function by modification of peptide structure: a minireview | |
| AU2002214938B2 (en) | Method for obtaining antigenic structures enhancing specific cross reactivity | |
| CA1271717A (en) | Polypeptides useful in vaccination against enteroviruses | |
| EP0597838B1 (en) | Vaccine compositions | |
| US4857634A (en) | Peptides useful in vaccination against enteroviruses | |
| GB2282813A (en) | Annular antigen scaffolds comprising thioether linkages | |
| NZ333562A (en) | Vaccine comprising antigens bound by thioester or disulphide bonds to fatty acid carriers such palmitic acid, antigens bound in reversible and labile way | |
| CA2696068A1 (en) | Compositions and methods for the treatment and prophylaxis of hypertension | |
| Garay et al. | Study of various presentation forms for a peptide mimetic of Neisseria meningitidis serogroup B capsular polysaccharide | |
| Cruz et al. | Study of different coupling agents in the conjugation of a V3‐based synthetic MAP to carrier proteins | |
| Kanda et al. | Dependence of the murine antibody response to an anti-CD4 CDR2 VH peptide on immunogen formulation | |
| Leibl et al. | Adjuvant/carrier activity of inactivated tick-borne encephalitis virus | |
| JPH05170797A (ja) | 環状ｈｉｖ主要中和決定基ペプチド | |
| JPH05271282A (ja) | 環状主要ｈｉｖ中和決定基とｔ細胞刺激エピトープとを含む合成ペプチド | |
| WO1987003883A2 (en) | Use of oligopeptides in the treatment of viral infections |